Pentoxifylline improves anemia through its novel effect on hypoxia-inducible factor-2 alpha in hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Pentoxifylline (PTX) significantly improved hemoglobin and reduced erythropoiesis-stimulating agent (ESA) doses in hemodialysis patients. PTX increased hypoxia-inducible factor-2 alpha (HIF-2α), suggesting a novel approach to managing anemia.
Area Of Science
- Nephrology
- Hematology
- Pharmacology
Background
- Anemia is a common complication in hemodialysis (HD) patients, often managed with erythropoiesis-stimulating agents (ESAs).
- ESA resistance is a significant challenge in treating anemia of HD patients.
- Hypoxia-inducible factor-2 alpha (HIF-2α) plays a role in erythropoiesis and may be a therapeutic target.
Purpose Of The Study
- To investigate the effect of pentoxifylline (PTX) on HIF-2α levels.
- To evaluate the efficacy of PTX in managing anemia in HD patients.
- To assess the impact of PTX on ESA requirements and ESA resistance index (ERI).
Main Methods
- A randomized, double-blind, placebo-controlled trial involving 80 HD patients.
- Patients received either 400 mg PTX or placebo twice daily for 6 months.
- Hemoglobin, hematocrit, ESA doses, ERI, HIF-2α, TGF-β1, and hs-CRP were measured.
Main Results
- PTX treatment led to a significant increase in hemoglobin and hematocrit levels.
- A significant reduction in ESA doses and ERI was observed in the PTX group.
- PTX administration resulted in a significant increase in HIF-2α and a decrease in TGF-β1 and hs-CRP.
Conclusions
- Pentoxifylline is a promising agent for correcting anemia in hemodialysis patients.
- The mechanism may involve the upregulation of HIF-2α.
- PTX may help overcome ESA resistance in HD patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Hemoglobin (Hb) is a crucial molecule in the human body, consisting of four polypeptide chains, each bound to an iron-containing heme group. This unique structure enables hemoglobin to bind to oxygen, with each molecule capable of combining with four molecules of oxygen, leading to rapid and reversible oxygen loading. When fully loaded with oxygen, it is called oxyhemoglobin, while hemoglobin that has released oxygen is called reduced hemoglobin or deoxyhemoglobin. As hemoglobin binds oxygen,...
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...